galantamine lactate | 807362-27-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: galantamine lactate
• 英文别名: 2-hydroxypropanoic acid;(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
• CAS: 807362-27-2
• 化学式: C₃H₆O₃*C₁₇H₂₁NO₃
• 分子量: 377.437
• InChiKey: HHJVWQHBWTWVFZ-XPSHAMGMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  99.5
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] SYNTHESIS OF MORPHINE AND RELATED DERIVATIVES<br/>[FR] SYNTHÈSE DE LA MORPHINE ET DE DÉRIVÉS ASSOCIÉS
  申请人：UNIV TEXAS

  公开号：WO2010132570A1

  公开（公告）日：2010-11-18

  The present invention relates to methods for the synthesis of galanthamine, morphine, intermediates, salts and derivatives thereof, wherein the starting compound is biphenyl.

  本发明涉及一种合成迷迭香碱、吗啡、中间体、盐和衍生物的方法，其中起始化合物为联苯。
• Carboxylate salts of galantamine and their pharmaceutical use
  申请人：Nastech Pharmaceutical Company Inc.

  公开号：US20040254146A1

  公开（公告）日：2004-12-16

  Disclosed are novel carboxylate salts of galantamine including galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate. These salts of galantamine have more than a 5 fold increase in solubility compared to galantamine hydrobromide. These galantamine salts can be administered to an individual to inhibit acetylcholinesterase in the treatment of such diseases as Alzheimer's disease, atony of the smooth muscle of the intestinal tract and urinary bladder, glaucoma, myasthenia gravis, and termination of the effects of competitive neuromuscular blocking drugs.

  本发明涉及新型加兰他敏的羧酸盐，包括加兰他敏葡萄糖酸盐、加兰他敏乳酸盐、加兰他敏柠檬酸盐和加兰他敏葡萄糖醛酸盐。与加兰他敏溴化物相比，这些加兰他敏盐的溶解度增加了5倍以上。这些加兰他敏盐可用于治疗阿尔茨海默病、肠道和膀胱平滑肌无力、青光眼、重症肌无力以及终止竞争性神经肌肉阻滞药的作用。可以将这些加兰他敏盐用于个体中，以抑制乙酰胆碱酯酶。
• Efficient Synthesis Of Morphine And Codeine
  申请人：Magnus Philip D.

  公开号：US20100292475A1

  公开（公告）日：2010-11-18

  The present invention relates to methods for the synthesis of morphine, intermediates, salts and derivatives thereof. In preferred embodiments, the invention relates to methods for improving the efficiency and overall yield of said morphine, morphine related derivatives and intermediates thereof. In further embodiments, the invention relates to methods for improving the efficiency and overall yield of galanthamine and intermediates thereof.

  本发明涉及吗啡、中间体、盐和衍生物的合成方法。在优选实施例中，本发明涉及改善吗啡、吗啡相关衍生物和中间体的效率和总产量的方法。在进一步实施例中，本发明涉及改善迷迭香碱及其中间体的效率和总产量的方法。
• Efficient Synthesis Of Galanthamine
  申请人：Magnus Philip D.

  公开号：US20100292466A1

  公开（公告）日：2010-11-18

  The present invention relates to methods for the synthesis of galanthamine, morphine, intermediates, salts and derivatives thereof. In preferred embodiments, the invention relates to methods for improving the efficiency and overall yield of said morphine, morphine related derivatives and intermediates thereof. In further embodiments, the invention relates to methods for improving the efficiency and overall yield of galanthamine and intermediates thereof.

  本发明涉及合成迷达唑啉、吗啡、中间体、盐和衍生物的方法。在优选实施例中，本发明涉及提高吗啡、吗啡相关衍生物和中间体的效率和总产率的方法。在进一步的实施例中，本发明涉及提高迷达唑啉及其中间体的效率和总产率的方法。
• Cross-conjugated 2,5-cyclohexadienone and related synthesis methods
  申请人：Magnus Philip D.

  公开号：US20100292489A1

  公开（公告）日：2010-11-18

  The present invention relates to methods for the synthesis of galanthamine, morphine, intermediates, salts and derivatives thereof. In preferred embodiments, the invention relates to methods for improving the efficiency and overall yield of said morphine, morphine related derivatives and intermediates thereof. In further embodiments, the invention relates to methods for improving the efficiency and overall yield of galanthamine and intermediates thereof.

  本发明涉及合成无花果碱、吗啡、中间体、盐和衍生物的方法。在优选实施例中，本发明涉及改善吗啡、吗啡相关衍生物和中间体的效率和总产率的方法。在进一步的实施例中，本发明涉及改善无花果碱及其中间体的效率和总产率的方法。